Plain-English translation of NCT06862908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can help people who have heart failure (where the heart doesn't pump as efficiently as it should) combined with obesity. Researchers want to understand whether this medication can improve symptoms and quality of life in people with specific types of heart failure who also struggle with weight.
Many people have both heart failure and obesity, and these conditions often make each other worse. This trial exists because doctors need new treatment options that can address both problems at the same time and help patients feel better and stay out of the hospital.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll have a 2-week screening period where doctors will check if you're eligible. Then you'll be randomly assigned to receive either the new medication at one of two doses or a placebo (inactive treatment) and will receive injections as scheduled over 52 weeks. You'll visit the clinic regularly so doctors can monitor how you're doing, and you'll keep a study diary to track your symptoms and health. The study includes a final 4-week safety follow-up period after treatment ends.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China